Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?
Williams
R O
RO
Kennedy Institute of Rheumatology, London, UK.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000918:Antibody Specificity; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000503:physiopathology* / Q000628:therapy*; D015704:CD4 Antigens / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000502:physiology; D016572:Cyclosporine / Q000627:therapeutic use; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006801:Humans; D016753:Interleukin-10 / Q000276:immunology; D018664:Interleukin-12 / Q000037:antagonists & inhibitors / Q000276:immunology; D051379:Mice; D011760:Pyrrolidinones / Q000494:pharmacology; D020889:Rolipram; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015704:CD4 Antigens; D011760:Pyrrolidinones; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D018664:Interleukin-12; D016572:Cyclosporine; D020889:Rolipram